Compare Costco Wholesale Corporation (COST) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Incyte Corporation — how do they compare? Costco Wholesale Corporation trades at $921.58 (market cap $408.78B), while Incyte Corporation trades at $112.62 (market cap $22.95B). The key difference: Costco Wholesale Corporation is far larger — about 17.8× Incyte Corporation's market cap, and Costco Wholesale Corporation pays a 0.64% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| COST | INCY | |
|---|---|---|
Market Cap | $408.78B | $22.95B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $118.52 |
52-Week Low | $849.63 | $67.38 |
Enterprise Value | $396.92B | $18.97B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $926.43, up 1.11% with strong fundamentals including 11.3% March sales growth and consistent earnings beats. The stock faces technical headwinds with bearish moving averages but maintains solid profitability with $8.1B net income and expanding margins. Recent membership fee increases and warehouse expansion support long-term growth, though high valuation multiples present near-term pressure.
Outlook remains positive with analyst consensus at $1,120 price target (65% buy ratings), but investors should monitor valuation sustainability amid technical weakness. Key risks include competitive pressures and economic sensitivity, while institutional accumulation and strong cash flow generation provide fundamental support.
Incyte (INCY) trades at $114.23, down 2.12% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.81, and revenue growth continues with 2025 revenue at $5.14 billion. Recent developments include positive Phase 1/2 data for VGA039 and the acquisition of Vega Therapeutics, expanding its hematology portfolio.
Outlook remains positive with analyst consensus favoring a Buy rating and a $112.78 price target. Key opportunities include pipeline advancements and robust profitability margins, while risks involve regulatory hurdles and competitive pressures in the biopharmaceutical sector. Earnings growth and product approvals are critical catalysts for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
